Drugs / 123-I Iodobenzovesamicol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00480701 | Feb 2007 → Oct 2011 | Alzheimer disease, Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 123-I Iodobenzovesamicol | “Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease” NCT00480701 ↗ |
| Known as | IBVM | “Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease” NCT00480701 ↗ |
| Modality | Diagnostic / imaging agent | “123-I IBVM SPECT imaging as a tool to assess cholinergic transporter binding in the brain of AD and PD research participants” NCT00480701 ↗ |
| Route | Other | “injection of 123-I IBVM” NCT00480701 ↗ |